OncoMatch/Clinical Trials/NCT05905887
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Is NCT05905887 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Rivoceranib Mesylate, Paclitaxel for gastrointestinal stromal tumors.
Treatment: Rivoceranib Mesylate, Paclitaxel — The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastrointestinal Stromal Tumor
Biomarker criteria
Required: KIT mutation
mutation in KIT or PDGFRα gene
Required: PDGFRA mutation
mutation in KIT or PDGFRα gene
Required: KIT overexpression (CD117+) (CD117(+))
CD117(+)
Required: ABCB1 overexpression (P-glycoprotein IHC score > 3) (IHC score > 3)
P-glycoprotin IHC score > 3
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: tyrosine kinase inhibitor (imatinib, sunitinib, regorafenib)
Failed (progressed and/or intolerable) after prior treatments for GIST, including at least imatinib and sunitinib, regorafenib.
Lab requirements
Blood counts
Neutrophil >1,500/mm3; Platelet > 100,000/mm3; Hemoglobin >8.0 g/dL
Kidney function
Creatinine <1.5 x ULN
Liver function
Total bilirubin < 1.5 x ULN; AST/ALT < 2.5 x ULN
Adequate bone marrow, hepatic, renal, and other organ functions Neutrophil >1,500/mm3 Platelet > 100,000/mm3 Hemoglobin >8.0 g/dL Total bilirubin < 1.5 x upper limit of normal (ULN) AST/ALT < 2.5 x ULN Creatinine <1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify